FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastrointestinal haemorrhage7 Gastroenteritis Eructation Gastritis Dysphagia
Estonian: Gastroenteriit Eruktatsioon Gastriit
English: Gynaecological haemorrhage Menstrual disorder Sexual dysfunction Testicular pain
Estonian: Günekoloogiline verejooks Menstruatsiooni häired
English: Syncope2
Estonian: Minestus2
English: Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment.
Estonian: Kerge või mõõduka neerukahjustusega patsientidelt on saadud vähe andmeid duloksetiini farmakokineetika kohta.
English: Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Lilly if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Estonian: Monoamiini oksüdaasi inhibiitorid (MAOI-d): Te ei tohi Duloxetine Lilly't kasutada koos MAOI-ga ega enne 14 päeva möödumist pärast MAOI ärajätmist.
English: Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant
Estonian: 25-aastastel psühhiaatrilise seisundiga täiskasvanutel esineb suurenenud enesekahjustusliku käitumise oht.
English: - This medicine has been prescribed for you only.
Estonian: Teie arst määrab teile siiski teie jaoks sobiva annuse.
English: Each capsule contains 60 mg of duloxetine (as hydrochloride).
Estonian: Iga kapsel sisaldab 60 mg duloksetiini (vesinikkloriidina).
English: • decreased thyroid gland activity which can cause tiredness or weight gain
Estonian: • kilpnäärme funktsiooni langus, mis põhjustab väsimust või kehakaalu tõusu
English: Hence, some patients that respond insufficiently to 60 mg may benefit from a higher dose.
Estonian: Seega võib 60 mg suurusele annusele mitteallunud patsientidele toimida annuse suurendamine.
English: Duloxetine Lilly contains sucrose.
Estonian: Duloxetine Lilly sisaldab sahharoosi.
English: b. Tabulated list of adverse reactions
Estonian: b. Kõrvaltoimete tabelloetelu
English: Each capsule contains 30 mg of duloxetine (as hydrochloride).
Estonian: Iga kapsel sisaldab 30 mg duloksetiini (vesinikkloriidina).
English: Uncommon side effects (may affect up to 1 in 100 people)
Estonian: Aeg-ajalt esinevad kõrvaltoimed (võivad esineda kuni 1-l inimesel 100-st)
English: Common side effects (may affect up to 1 in 10 people)
Estonian: Sagedad kõrvaltoimed (võivad esineda kuni 1-l inimesel 10-st)
English: Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials.
Estonian: Maksimaalsed uuritud annused olid 120 mg ööpäevas, mida manustati kaheks võrdseks annuseks jagatuna.
English: Serotonin syndrome6
Estonian: Serotoniinisündroom6 Krambid1
English: Paraesthesia
Estonian: Eritumine
English: Psychiatric disorders Insomnia
Estonian: Psühhiaatrilised häired Unetus
English: Duloxetine Lilly 60 mg Gelatin
Estonian: Duloxetine Lilly 60 mg Želatiin
English: Major depressive disorder
Estonian: Depressiooni ravi.
English: Blurred vision Mydriasis Visual impairment
Estonian: Silma kahjustused Hägune nägemine
English: Vascular disorders
Estonian: Orgasmi häired
English: Oral use.
Estonian: Manustamisviis Suukaudne.
English: Orgasm abnormal Abnormal dreams
Estonian: Ebatavalised unenäod
English: Duloxetine Lilly 30 mg Gelatin
Estonian: Duloxetine Lilly 30 mg Želatiin
English: Dry mouth
Estonian: Kutaanne vaskuliit
English: • muscle tightness, muscle twitching
Estonian: • halb enesetunne (iiveldus), suukuivus
English: Package leaflet: information for the user
Estonian: Pakendi sisu ja muu teave
English: Breast-feeding mothers
Estonian: Rinnaga toitvad emad
English: Duloxetine is very weakly excreted into human milk based on a study of 6 lactating patients, who did not breast feed their children.
Estonian: Uuringu põhjal, kus osales 6 lakteerivat patsienti, kes oma lapsi ei imetanud, leiti, et duloksetiin eritub väga väheses koguses rinnapiima.
English: Hepatic impairment
Estonian: Lihaste kramp
English: Povidone
Estonian: ABIAINED
English: Aggression and anger4
Estonian: Hallutsinatsioonid Agressiivsus ja viha
English: Shellac
Estonian: Sahharoos
English: Contains sucrose See leaflet for further information
Estonian: Lisainformatsiooni saamiseks vt pakendi infolehte
English: Nervousness
Estonian: Suukuivus
English: Urine flow decreased
Estonian: Uriinijoa nõrkus
English: Chest pain7
Estonian: Valu rinnus7
English: • weight gain
Estonian: • kehakaalu tõus
English: Vertigo Ear pain
Estonian: Peapööritus Kõrvavalu
English: Anaphylactic reaction
Estonian: Anafülaktiline reaktsioon Ülitundlikkushäire
English: • blurred eyesight
Estonian: • ähmane nägemine
English: Duloxetine Lilly 30 mg hard gastro-resistant capsules duloxetine
Estonian: RAVIMPREPARAADI NIMETUS Duloxetine Lilly 30 mg gastroresistentsed kõvakapslid duloksetiin
English: Trismus
Estonian: • isutus
English: Duloxetine Lilly 60 mg hard gastro-resistant capsules duloxetine
Estonian: RAVIMPREPARAADI NIMETUS Duloxetine Lilly 60 mg gastroresistentsed kõvakapslid duloksetiin
English: Hypromellose acetate succinate Sucrose
Estonian: Hüpromelloosatsetaatsuktsinaat Sahharoos
English: Contents of the pack and other information What Duloxetine Lilly contains
Estonian: Kuidas Duloxetine Lilly välja näeb ja pakendi sisu Duloxetine Lilly on gastroresistentne kõvakapsel.
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients Capsule content:
Estonian: 6.1 Abiainete loetelu
English: Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.
Estonian: Euroopa Ravimiamet vaatab kogu uue teabe igal aastal läbi ja vajaduse korral uuendab käesolevat kokkuvõtet.
English: What measures are being taken to ensure the safe and effective use of Obizur?
Estonian: Mis meetmed võetakse, et tagada Obizuri ohutu ja efektiivne kasutamine?
English: Obizur was not compared with any other medicine.
Estonian: Obizuri ei võrreldud teiste ravimitega.
English: A risk management plan has been developed to ensure that Obizur is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Obizuri võimalikult ohutu kasutamine.
English: What is Obizur and what is it used for?
Estonian: Mis on Obizur ja milleks seda kasutatakse?
English: All 28 patients showed a positive response within 24 hours of starting treatment with Obizur; in 24 out of 28 patients, the bleeding stopped completely.
Estonian: Kõigil 28 patsiendil esines 24 tunni jooksul Obizuriga ravi alustamisest positiivne ravivastus; 24 patsiendil 28st peatus verejooks täielikult.
English: The full EPAR and risk management plan summary for Obizur can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Obizuri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Why is Obizur approved?
Estonian: Miks Obizur heaks kiideti?
English: Hypersensitivity (allergic) reactions may occur with Obizur, and can include angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, hypotension (low blood pressure), feeling tired or restless, nausea (feeling sick) or vomiting, tachycardia (rapid heartbeat), tightness of the chest, wheezing and tingling sensations.
Estonian: Obizuriga võib esineda ülitundlikkusreaktsioone (allergiareaktsioone), sh angioödeem (nahaaluste kudede turse), põletus- ja kipitustunne süstekohal, külmavärinad, õhetus, sügelev lööve, peavalu, nõgeslööve, madal vererõhk, väsimus või rahutus, iiveldus või oksendamine, tahhükardia (kiirenenud südametegevus), rõhumistunne rinnus, vilistav hingamine ja kirvendus.
English: In some cases, reactions become severe (anaphylaxis) and may be associated with dangerously steep falls in blood pressure.
Estonian: Mõnel juhul võib reaktsioon muutuda raskeks (anafülaksia) ja sellega võib kaasneda vererõhu ohtlikult järsk langus.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Obizur are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Obizuri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The dose, and how often it is given, as well as the length of treatment, are adjusted depending on the patient's condition and requirements, and the degree of danger posed by the bleeding.
Estonian: Annuse, manustamissageduse ja ravi kestuse määramisel lähtutakse patsiendi seisundist ja vajadustest ning verejooksust tingitud ohu raskusastmest.
English: Factor VIII is one of the proteins needed for normal clotting of the blood.
Estonian: VIII hüübimistegur on üks normaalseks verehüübimiseks vajalikest valkudest.
English: Other information about Obizur
Estonian: Muu teave Obizuri kohta
English: This is because it has not been possible to obtain complete information about Obizur due to the rarity of the disease.
Estonian: See tähendab, et harvaesineva haiguse tõttu ei olnud võimalik saada Obizuri kohta täielikku teavet.
English: Obizur susoctocog alfa
Estonian: Obizur alfasusoktokog
English: Since Obizur has been approved under exceptional circumstances, the company that markets the medicine will establish and maintain a patient registry to collect and analyse short- and long-term data on the effectiveness and safety of Obizur in patients with acquired haemophilia caused by antibodies against factor VIII.
Estonian: Et Obizur kiideti heaks erandkorras, koostab ravimit turustav ettevõte patsiendiregistri ja hoiab seda ajakohasena, et koguda ja analüüsida lühikeses ja pikas perspektiivis andmeid Obizuri efektiivsuse ja ohutuse kohta VIII hüübimisteguri vastaste antikehade põhjustatud omandatud hemofiiliaga patsientidel.
English: susoctocog alfa, works in the body in the same way as human factor VIII, but has a slightly different shape.
Estonian: Obizuri toimeaine alfasusoktokog toimib organismis samamoodi kui inimese VIII hüübimistegur, kuid on veidi teistsuguse ehitusega.
English: What are the risks associated with Obizur?
Estonian: Mis riskid Obizuriga kaasnevad?
English: With regard to safety, the Committee considered that the potential for allergic reactions and the development of antibodies against the medicine is expected, and is outweighed by the beneficial effects.
Estonian: Ohutuse suhtes leidis inimravimite komitee, et allergiareaktsioonide ja ravimivastaste antikehade tekke risk on eeldatav ning ravimi kasulikkus on sellest riskist suurem.
English: What information is still awaited for Obizur?
Estonian: Mis teavet Obizuri kohta veel oodatakse?
English: Obizur contains the active substance susoctocog alfa.
Estonian: Obizur sisaldab toimeainena alfasusoktokogi.
English: The response to Obizur was considered positive if bleeding stopped or was reduced, while a negative response meant that the bleeding continued or worsened.
Estonian: Obizuri positiivseks ravivastuseks loeti verejooksu peatumist või vähenemist ja negatiivseks ravivastuseks verejooksu jätkumist või süvenemist.
English: The results of the main study showed that Obizur was effective in treating serious bleeding episodes in adults with the disorder.
Estonian: Põhiuuringu tulemused tõendasid Obizuri efektiivsust selle häirega täiskasvanutel esinevate raskete verejooksuepisoodide ravis.
English: As a result, it will not be as easily recognised by the antibodies and it can replace the human factor VIII that has been inactivated, thereby helping the blood to clot and controlling the bleeding.
Estonian: Selle tulemusel ei tunne antikehad alfasusoktokogi sama kergesti ära ja see saab asendada inhibeeritud VIII hüübimistegurit, aidates verel hüübida ja piirata verejooksu.
English: For the full list of all side effects and restrictions with Obizur, see the package leaflet.
Estonian: Obizuri kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It is not intended to provide practical advice on how to use Obizur.
Estonian: Hindamisaruandes ei anta Obizuri kasutamise praktilisi nõuandeid.
English: Obizur has been investigated in one main study involving 28 adult patients with acquired haemophilia caused by antibodies against factor VIII who were experiencing a serious bleeding episode.
Estonian: Obizuri on uuritud ühes põhiuuringus, milles osales 28 täiskasvanud patsienti, kellel oli VIII hüübimisteguri vastaste antikehade põhjustatud omandatud hemofiilia ning kellel esines raskeid verejooksuepisoode.
English: Additionally, the company that markets Obizur will provide healthcare professionals who are expected to use Obizur with educational material containing information on how to calculate the dose.
Estonian: Lisaks varustab Obizuri turustav ettevõte Obizuri eeldatavasti määravad tervishoiuspetsialistid teabematerjaliga, mis sisaldab annuse arvutamise teavet.
English: Obizur must not be used in patients who have had a severe allergic reaction to susoctocog alfa, any of its other ingredients, or hamster protein.
Estonian: Obizuri ei tohi kasutada patsiendid, kellel on esinenud alfasusoktokogi, selle ravimi mis tahes muu koostisaine või hamstrivalkude suhtes tugevaid allergiareaktsioone.
English: Obizur can only be obtained with a prescription and treatment should be supervised by a doctor with experience in the treatment of haemophilia.
Estonian: Obizur on retseptiravim ja ravi peab toimuma hemofiilia ravis kogenud arsti järelevalve all.
English: For practical information about using Obizur, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Obizuri kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Patients with acquired haemophilia caused by antibodies against factor VIII have blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Estonian: VIII hüübimisteguri vastaste antikehade põhjustatud omandatud hemofiiliaga patsientidel esineb hüübimishäireid, näiteks liigeste, lihaste või siseelundite verejookse.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Obizur, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Obizuri omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This is a summary of the European public assessment report (EPAR) for Obizur.
Estonian: See on ravimi Obizur Euroopa avaliku hindamisaruande kokkuvõte.
English: How does Obizur work?
Estonian: Kuidas Obizur toimib?
English: For more information about treatment with Obizur, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Obizuriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients with acquired haemophilia caused by antibodies against factor VIII may develop antibodies against susoctocog alfa.
Estonian: VIII hüübimisteguri vastaste antikehade põhjustatud omandatud hemofiiliaga patsientidel võivad tekkida alfasusoktokogi vastased antikehad.
English: Obizur is available as a powder and solvent that are mixed together to make a solution for injection into a vein.
Estonian: Obizuri turustatakse pulbri ja lahustina, millest segatakse kokku veeni manustatav süstelahus.
English: How is Obizur used?
Estonian: Kuidas Obizuri kasutatakse?
English: Obizur has been authorised under ‘exceptional circumstances'.
Estonian: Obizuri müügiluba anti erandkorras.
English: What benefits of Obizur have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Obizuri kasulikkus?
English: The CHMP noted the lack of specific treatments for acquired haemophilia caused by antibodies against factor VIII.
Estonian: Inimravimite komitee märkis, et VIII hüübimisteguri vastaste antikehade põhjustatud omandatud hemofiilia spetsiifilised ravimeetodid puuduvad.
English: Obizur is a medicine used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.
Estonian: Obizur on omandatud hemofiiliaga (VIII hüübimistegurit inhibeerivate antikehade spontaansest tekkest põhjustatud hüübimishäire) täiskasvanutel verejooksuepisoodide raviks kasutatav ravim.
English: --1 Recombinant Protein Q from Leishmania infantum MON-1 ≥ 36.7 ELISA Units (EU)* * Antigen content determined in an ELISA against an internal standard.
Estonian: --1 Leishmania infantum'i MON-1-st toodetud rekombinantne Q-valk ≥ 36,7 ELISA ühikut (EÜ)* * Antigeenisisaldus määratud ELISA meetodil ettevõttesisese standardi alusel.
English: Lyophilisate: 1 vial; solvent:
Estonian: 1 viaal; lahusti: 1 viaal
English: 1 Vial
Estonian: 1 viaali
English: 10 mg/ ml Solution for injection.
Estonian: INCRELEX 10 mg/ml Süstelahus
English: Subcutaneous use Vial (glass)
Estonian: Subkutaanne viaalis (klaasist) 4 ml
English: Packaging
Estonian: Pakendi sisu
English: Other information about Aerinaze
Estonian: Muu teave Aerinaze kohta
English: This means that patients only need to take the tablet twice a day.
Estonian: See tähendab, et patsientidel on vaja võtta tablett ainult kaks korda ööpäevas.
English: Similar results were seen in the second study.
Estonian: Teise uuringu tulemused olid sarnased.
English: This summary was last updated in 10-2011.
Estonian: Kokkuvõtte viimane uuendus: 10-2011.
English: The full EPAR for Aerinaze can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Aerinaze kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients.
Estonian: Aerinaze efektiivsust hinnati kahes uuringus, milles osales kokku 1248 täiskasvanut ja noorukit.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aerinaze on 30 July 2007.
Estonian: Euroopa Komisjon andis Aerinaze müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. juulil
English: What is the risk associated with Aerinaze?
Estonian: Mis riskid Aerinazega kaasnevad?
English: The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started, and over the entire 15 days of treatment.
Estonian: Efektiivsuse põhinäitaja oli heinanohu sümptomite raskuse muutumine patsientide teadete järgi enne ravi algust ja kogu 15-päevase ravi jooksul.
English: It should not be used in people who are taking a monoamine oxidase inhibitor (such as some medicines used to treat depression) or who have stopped taking one of these medicines within the last two weeks.
Estonian: Seda ei tohi kasutada inimesed, kes kasutavad mõnda monoaminooksüdaasiinhibiitorit (näiteks teatud depressiooniravimid) või kes on lõpetanud kahel viimasel nädalal mõne sellise ravimi kasutamise.
English: What is Aerinaze?
Estonian: Mis on Aerinaze?
English: In adults and adolescents over 12 years of age, the recommended dose of Aerinaze is one tablet twice a day, taken whole with a full glass of water.
Estonian: Täiskasvanutel ja üle 12 aasta vanustel noorukitel on Aerinaze soovitatav annus üks tablett kaks korda ööpäevas, mis manustatakse tervena koos klaasi veega.
English: Desloratadine has been available in the European Union (EU) since 2001, and pseudoephedrine is widely used in medicines that have been available over-the-counter for many years.
Estonian: Desloratadiini on Euroopa Liidus turustatud alates 2001. aastast ja pseudoefedriini kasutatakse laialdaselt ravimites, mida on turustatud palju aastaid käsimüügiravimitena.
English: Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone.
Estonian: Aerinaze vähendas sümptomeid efektiivsemini kui kumbki toimeaine eraldi.
English: Why has Aerinaze been approved?
Estonian: Miks Aerinaze heaks kiideti?
English: The patients recorded their symptoms in a diary every 12 hours during the study, scoring on a standard symptom scale how severe the symptoms were over the previous 12-hour period.
Estonian: Patsiendid märkisid uuringu vältel iga 12 tunni järel päevikusse sümptomite raskuse viimase 12 tunni jooksul, lähtudes standardsest sümptomiskaalast.
English: For more information about treatment with Aerinaze, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Aerinazega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In Aerinaze, the two active substances are used together, since an antihistamine alone may not provide adequate relief for patients with nasal congestion.
Estonian: Aerinazes kasutatakse neid kaht toimeainet koos, sest ainult antihistamiin ei pruugi patsientidel ninakinnisust piisavalt leevendada.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerinaze.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Aerinaze is a medicine containing the active substances desloratadine (2.5 mg) and pseudoephedrine (120 mg).
Estonian: Aerinaze on ravim, mis sisaldab toimeainetena desloratadiini (2,5 mg) ja pseudoefedriini (120 mg).
English: Treatment should continue for as short a time as possible and should stop when symptoms, chiefly the congestion (blocked nose), have disappeared.
Estonian: Ravi kestus peab olema võimalikult lühike ja sümptomite, põhiliselt ninakinnisuse kadumisel tuleb ravi lõpetada.
English: Desloratadine/pseudoephedrine
Estonian: Kokkuvõte üldsusele desloratadiin/pseudoefedriin
English: It is available as blue and white modified-release tablets.
Estonian: Seda turustatakse sini-valgete toimeainet modifitseeritult vabastavate tablettidena.
English: This is a summary of the European public assessment report (EPAR) for Aerinaze.
Estonian: See on ravimi Aerinaze Euroopa avaliku hindamisaruande kokkuvõte.
English: ‘Modified-release' means that the tablets have been made to allow one of the active substances to be released immediately and the other one released over a few hours.
Estonian: Modifitseeritult vabastamine tähendab, et tablettidest vabaneb üks toimeaine kiiresti ja teine aeglaselt.
English: For the full list of all side effects reported with Aerinaze, see the Package Leaflet.
Estonian: Aerinaze kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: This reduces the amount of fluid released from the vessels, resulting in less swelling and less mucus production in the nose.
Estonian: See vähendab veresoontest vabaneva vedeliku hulka, mille tulemusena turse väheneb ja ninas tekib vähem eritist.
English: In both studies, Aerinaze was compared with desloratadine alone and with pseudoephedrine alone.
Estonian: Mõlemas uuringus võrreldi Aerinazet ainult desloratadiini ja ainult pseudoefedriiniga.
English: Desloratadine is released from its layer immediately after it is taken, while pseudoephedrine is released slowly over 12 hours.
Estonian: Desloratadiin vabaneb kohe pärast manustamist ja pseudoefedriin aeglaselt, 12 tunni jooksul.